Your browser's JavaScript is disabled.

To properly view the content on this page, please enable JavaScript.

Publications

Future Oncology

All Publications

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design

Clinical Imetelstat: MF Imetelstat

Future Oncology 2022

Mascarenhas, et al.

[facetwp facet="publication_load_more"]